You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma
|
|---|---|
| Published in |
Clinical Cancer Research, January 2013
|
| DOI | 10.1158/1078-0432.ccr-12-2693 |
| Pubmed ID | |
| Authors |
Kimberley Jones, Frank Vari, Colm Keane, Pauline Crooks, Jamie P. Nourse, Louise A. Seymour, David Gottlieb, David Ritchie, Devinder Gill, Maher K. Gandhi |
| Abstract |
Candidate circulating disease response biomarkers for classical Hodgkin lymphoma (cHL) might arise from Hodgkin-Reed-Sternberg (HRS) cells or nonmalignant tumor-infiltrating cells. HRS cells are sparse within the diseased node, whereas benign CD163(+) M2 tissue-associated macrophages (TAM) are prominent. CD163(+) cells within the malignant node may be prognostic, but there is no data on serum CD163 (sCD163). The HRS-specific serum protein sTARC shows promise as a disease response biomarker. Tumor-specific and tumor-infiltrating circulating biomarkers have not been compared previously. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Netherlands | 1 | 1% |
| Unknown | 80 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 16% |
| Student > Bachelor | 13 | 16% |
| Student > Ph. D. Student | 10 | 12% |
| Other | 7 | 9% |
| Student > Master | 7 | 9% |
| Other | 20 | 24% |
| Unknown | 12 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 35 | 43% |
| Agricultural and Biological Sciences | 12 | 15% |
| Immunology and Microbiology | 8 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 2 | 2% |
| Other | 7 | 9% |
| Unknown | 15 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 December 2023.
All research outputs
#6,010,002
of 22,689,790 outputs
Outputs from Clinical Cancer Research
#5,613
of 12,572 outputs
Outputs of similar age
#65,170
of 282,270 outputs
Outputs of similar age from Clinical Cancer Research
#51
of 169 outputs
Altmetric has tracked 22,689,790 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 12,572 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one has gotten more attention than average, scoring higher than 54% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 282,270 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 169 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.